Infant Bacterial Therapeutics AB (publ) (9IB.SG)
- Previous Close
7.16 - Open
7.12 - Bid 7.20 x --
- Ask 7.52 x --
- Day's Range
7.12 - 7.20 - 52 Week Range
3.56 - 9.24 - Volume
0 - Avg. Volume
102 - Market Cap (intraday)
101.391M - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.85 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.
www.ibtherapeutics.comRecent News: 9IB.SG
Performance Overview: 9IB.SG
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9IB.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9IB.SG
Valuation Measures
Market Cap
100.83M
Enterprise Value
72.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.01%
Return on Equity (ttm)
-38.65%
Revenue (ttm)
77k
Net Income Avi to Common (ttm)
-123.07M
Diluted EPS (ttm)
-0.85
Balance Sheet and Cash Flow
Total Cash (mrq)
329.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-64.36M
Company Insights: 9IB.SG
9IB.SG does not have Company Insights